News & Media

Press release Events

Press release 2023/08/18 Regulatory

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2023

Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima® April – June Financial...

Press release 2023/08/14

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment The patient who...

Press release 2023/08/07

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/06/19

Medivir's patent application for fostrox approved in China

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/06/02

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/06/01

Medivir to present at the Redeye Growth Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/05/31 Regulatory

Change in the number of shares and votes in Medivir AB (publ)

Stockholm – Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has...

Press release 2023/05/30

Medivir to present at the ABGSC Life Science Summit

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Press release 2023/05/16

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023

In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) (“Medivir”) on 4 May 2023...

Press release 2023/05/04 Regulatory

Execution of the annual general meeting’s resolution on the removal of share class in Medivir AB (publ)

The annual general meeting in Medivir AB (publ), held earlier today on 4 May 2023, resolved to adopt new articles of...

Press release 2023/05/04 Regulatory

Resolutions at the Annual General Meeting in Medivir on 4 May 2023

Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by physical...

Press release 2023/04/27 Regulatory

MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2023

“Thanks to the strong interest from clinicians and patients, we were able to swiftly dose the first patients in the phase...